The OSIRIS ECPR Trial
Launched by GENERAL UNIVERSITY HOSPITAL, PRAGUE · Jan 30, 2025
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The OSIRIS ECPR Trial is a research study looking at two different methods of helping people who experience a cardiac arrest outside of a hospital. One approach is called extracorporeal cardiopulmonary resuscitation (ECPR), which uses a special machine to support the heart and lungs, while the other is the traditional method of cardiopulmonary resuscitation (CPR). The study aims to see which method works better for patients who have a specific type of cardiac arrest known as ventricular fibrillation or pulseless ventricular tachycardia.
To be part of this trial, participants need to be between 18 and 70 years old, have had a witnessed cardiac arrest, and received CPR from bystanders. They should also have a documented shockable heart rhythm and must meet certain health conditions. If someone joins the trial, they will receive either ECPR or standard CPR based on a random selection process. It’s important to note that this trial is not yet recruiting participants, but it represents a significant effort to improve outcomes for patients who suffer sudden cardiac arrest.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 and ≤ 70 years presumed or known
- • 2. Witnessed OHCA
- • 3. Bystander CPR provided
- • 4. Presumed cardiac or unknown cause
- • 5. An initial documented shockable rhythm of VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia)
- • 6. Minimum of ≥ 10 min of ACLS without ROSC or at least ≥ 3 defibrillations in ongoing VF/pulseless VT
- • 7. Body morphology able to accommodate a mechanical chest compression device
- • 8. ECPR team and intensive care unit (ICU) capacity in the receiving center available
- • 9. Estimated transfer time from the scene to the hospital ≤ 30 minutes or to the scene ≤ 30 minutes
- • 10. Eligible for intensive care without restrictions or limitations
- Exclusion Criteria:
- • 1. ACLS ≥ 30 minutes before randomization
- • 2. Known limitations in care or a Do Not Attempt to Resuscitate (DNAR) order
- • 3. Known severe disease making 90-day survival unlikely
- • 4. Known bleeding diathesis or acute or recent intracranial bleeding
- • 5. Known, obvious or suspected pregnancy
- • 6. Known pre-arrest severe cognitive dysfunction (mRS ≥ 4)
- • 7. Known hypothermia as a cause of cardiac arrest
About General University Hospital, Prague
General University Hospital in Prague is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to facilitate cutting-edge studies across various therapeutic areas. Committed to improving patient outcomes and contributing to the global medical community, the hospital collaborates with various stakeholders, including academic partners, pharmaceutical companies, and regulatory bodies, to ensure the highest standards of clinical research. Its focus on ethical practices and patient safety underscores its role as a trusted leader in clinical trial sponsorship.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jan Bělohlávek, MD, PhD
Principal Investigator
General University Hospital, Prague
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported